Shaanxi Panlong Pharmaceutical (002864.SZ): Fluibuprofen patch approved for clinical trials.

17:31 02/02/2026

Plandragon Pharmaceuticals (002864.SZ) announced that the company has received the Drug Clinical Trial Approval Notification issued by the National Medical Products Administration, approving the clinical trial of fluorofenbuprofen patches. The related indications for pain relief and anti-inflammation include the following diseases and symptoms: osteoarthritis, periarthritis of the shoulder joint, tendinitis and tenosynovitis, tendinopathy, lateral epicondylitis of the humerus (such as tennis elbow), muscle pain, swelling and pain after trauma.

Shaanxi Panlong Pharmaceutical (002864.SZ) announced that the company has received the approval notice for clinical trial of flurbiprofen patch issued by the National Medical Products Administration, allowing the company to conduct clinical trials. The relevant indications are pain relief and anti-inflammatory effects for the following diseases and symptoms: osteoarthritis, periarthritis of the shoulder joint, tendinitis and tenosynovitis, tendinosis, lateral epicondylitis (such as tennis elbow), muscle pain, swelling and pain after trauma.

Espressif Systems (688018.SH) plans to repurchase 50 million to 100 million yuan.

On February 2nd, JIUMAOJIU (09922) spent 2.0029 million Hong Kong dollars to repurchase 96.1 million shares.

Yitai Think Tank (688816.SH): The final winning rate of online issuance is approximately 0.0222%.

Espressif Systems (688018.SH) plans to repurchase 50 million to 100 million yuan.

On February 2nd, JIUMAOJIU (09922) spent 2.0029 million Hong Kong dollars to repurchase 96.1 million shares.

Yitai Think Tank (688816.SH): The final winning rate of online issuance is approximately 0.0222%.